| Aug 16 |
AstraZeneca Imfinzi label expanded in U.S. for lung cancer
|
| Aug 16 |
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
|
| Aug 16 |
AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review
|
| Aug 15 |
These 10 drugs will be cheaper after Medicare negotiations
|
| Aug 15 |
Medicare negotiates lower prices for 10 high-cost drugs
|
| Aug 15 |
Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.
|
| Aug 15 |
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
|
| Aug 15 |
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
|
| Aug 15 |
Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations
|
| Aug 15 |
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
|
